We have located links that may give you full text access.
ENGLISH ABSTRACT
JOURNAL ARTICLE
[Cardiotoxic study of aclacinomycin A. Subacute cardiotoxicity of aclacinomycin A and its recovery in hamsters (author's transl)].
Japanese Journal of Antibiotics 1980 March
Male golden hamsters were treated with aclacinomycin A or adrianmycin by daily intraperitoneal injections for 15 consecutive days, and then allowed to be recovered for 15 days. Dose levels of aclacinomycin A and adriamycin were 1.5, 2.0 and 3.0 mg/kg, and 0.17 and 0.5 mg/kg, respectively. General toxicity, electrocardiogram (ECG), blood biochemical analysis and light microscopic and electron microscopic examinations were studied. The two drugs produced body weight loss at a dose of 3.0 mg/kg and 0.5 mg/kg, respectively. Death occurred in hamsters treated with aclacinomycin A at the highest dose (4/6 animals). In ECG study, aclacinomycin A-treated hamsters showed reversible QRS duration prolongation and T wave flattening at a dose of 1.5 or 2.0 mg/kg. Adriamycin-treated animals at a dose of 0.5 mg/kg showed R wave amplitude elevation during dosing period, and PR interval prolongation, R wave amplitude elevation and S wave amplitude reduction during recovery period. Blood biochemical analysis demonstrated reversible elevation of lactate dehydrogenase and alpha-hydroxybutyrate dehydrogenase activities in aclacinomycin A-treated hamsters at a dose of 2.0 mg/kg, and an increase in lipoperoxide in adriamycin-treated animals at a dose of 0.5 mg/kg during dosing period. Histologically, both drugs produced separation of myofilaments, swelling of mitochondria, dilation of sarcoplasmic reticulums and decreases in glycogen and lipid particles in myocardium. But aclacinomycin A-treated hamsters rarely showed these alterations after recovery period, whereas adriamycin-treated animals showed separation and necrosis of myofilaments, fibrosis of muscle fibers and formation of myelin figure even after recovery period. These results suggested that cardiotoxicity caused by aclacinomycin A was reversible and milder than that by adriamycin.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app